Answers are grounded in this paper and cite their sources.
Tarlatamab is a bispecific T-cell engager that has demonstrated promising efficacy in treating patients with relapsed small cell lung cancer (SCLC). The incidence of immune-mediated adverse events, including cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome (ICANS), has been reported at relatively low frequencies, with severe events occurring in a minority of patients. Consequently, real-world experience in managing severe ICANS associated with tarlatamab remains limited. We present a case of relapsed SCLC treated with tarlatamab that was complicated by recurrent episodes of severe ICANS. Subsequent administrations incorporated prophylactic anakinra, an interleukin-1 receptor antagonist, to mitigate neurotoxicity, which was well-tolerated and enabled the continuation of therapy, eliciting a significant clinical and radiographic response, including intracranial response. This case warrants further study of interleukin-1 blockade as a potential strategy for ICANS prophylaxis in patients with SCLC who may be at a higher risk for severe ICANS when treated with bispecific antibody therapy.
No takes yet. Share an insight, caveat, or question.
Shia et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: